Loading organizations...
Flexus Biosciences is a San Carlos, California-based biotechnology company focused on discovering and developing small-molecule cancer immunotherapies that target regulatory T cells. The organization develops therapeutic agents designed to reverse tumor immunosuppression by targeting the host immune system, advancing a lead clinical asset known as the IDO1-inhibitor F001287. Prior to its strategic exit, the enterprise raised $38 million in venture capital funding from prominent institutional investors including Kleiner Perkins Caufield & Byers, The Column Group, and Celgene. In February 2015, the business was acquired by Bristol-Myers Squibb for a total valuation of $1.25 billion, consisting of an $800 million upfront payment and $450 million in contingent developmental milestones. Following this transaction, the leadership team spun out remaining cancer candidates to form Arcus Biosciences. Flexus Biosciences was founded in 2013 by Terry Rosen and Juan Jaen.
Flexus Biosciences has raised $66.0M across 3 funding rounds.
Flexus Biosciences has raised $66.0M in total across 3 funding rounds.
Flexus Biosciences has raised $66.0M across 3 funding rounds. Most recently, it raised $15.0M Series U in March 2015.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2015 | $15M Series U | — | Endeavor Venture Funds, Mott Family Capital, MPM Capital, Westlake Village BioPartners | Announced |
| Dec 1, 2014 | $38M Series B | — | 5AM Ventures, Endeavor Venture Funds, Mott Family Capital, MPM Capital, OrbiMed, The Column Group, Westlake Village BioPartners, Celgene, Beth Seidenberg | Announced |
| Sep 1, 2013 | $13M Series A | — | Endeavor Venture Funds, Mott Family Capital, MPM Capital, Westlake Village BioPartners | Announced |
Flexus Biosciences has raised $66.0M in total across 3 funding rounds.
Flexus Biosciences's investors include Endeavor Venture Funds, Mott Family Capital, MPM Capital, Westlake Village BioPartners, 5AM Ventures, OrbiMed, The Column Group, Celgene, Beth Seidenberg.
Flexus Biosciences was a biotechnology company founded in 2013 that developed small-molecule cancer immunotherapies targeting regulatory T cells to reverse tumor immunosuppression through its Agents for Reversal of Tumor Immunosuppression (ARTIS) platform.[1][2][3][4] It served oncology patients and researchers by addressing immune evasion in tumors, raising $53.2M before its acquisition by Bristol-Myers Squibb in February 2015 for $800M upfront (plus up to $450M in milestones), marking rapid growth from inception to exit in under two years.[1][3][4]
Flexus was formed in 2013 in San Carlos, California, by seasoned researchers from biotech and pharma industries, including CEO Terry Rosen and R&D head Juan Jaen, backed by top life sciences venture capital (initially $38M raised).[1][2][3][4] The idea stemmed from "Goldilocks targets" like IDO1 and TDO2—validated enzymes that shield tumors from the immune system but overlooked by others—leading to quick assembly of a 30+ scientist team that generated IDO1 inhibitors and secured the Bristol-Myers Squibb deal.[3] Early traction came from unexploited immunology insights, with job postings for quantitative biology roles signaling aggressive hiring in late 2013.[2]
Flexus rode the mid-2010s immuno-oncology boom, where checkpoint inhibitors like PD-1 were transforming cancer treatment, by complementing them with small-molecule agents targeting complementary immunosuppression pathways like IDO/TDO.[1][4] Timing was ideal amid surging VC interest in Bay Area biotech, with Flexus's quick pivot from funding to $1.25B potential acquisition validating small-molecule immuno-oncology's potential alongside biologics.[3][4] It influenced the ecosystem by accelerating Bristol-Myers Squibb's pipeline (adding IDO1 inhibitor and discovery programs) and spawning Arcus Biosciences, led by Rosen and Jaen, which advanced related adenosine/PD-1 drugs post-spinout.[1][3]
Flexus's legacy endures through its absorbed assets in Bristol-Myers Squibb's immuno-oncology arsenal and the founders' Arcus Biosciences, which went public and progressed Phase 1 trials on next-gen inhibitors by 2018.[1] Evolving trends like combination therapies and adenosine targeting will likely amplify its indirect impact, as tumors' immune evasion remains a core challenge. This swift biotech archetype—from insight to blockbuster exit—continues shaping how startups humanize cancer therapy via immunology's untapped edges.
